Eptinezumab-jjmr (Vyepti)

Eptinezumab‑jjmr (Vyepti) is covered for prevention of migraine in adults ≥18 with ≥4 monthly migraine days and is not covered for patients <18 or non‑FDA indications; approval is up to 300 mg IV every 3 months with authorization for one year. Key requirements: documented trials of ≥2 standard prophylactic agents from different classes with inadequate efficacy or intolerable AEs (or one ineffective + one intolerable), trial of ≥1 triptan or documented contraindication to triptans, and documentation of age, baseline migraine frequency, prior therapy names/outcomes, and planned/actual IV dosing/administration.

"Patient is 18 years of age or older"

Sign up to see full coverage criteria, indications, and limitations.